Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests
On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation...
The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The world needs a signal that multilateralism works: ML&P opening statement to the INB13,...
Thank you for the opportunity to make a brief statement.
The negotiations for the Pandemic Agreement enter the final phase. We hope and wish for...
Medicines Law & Policy statement at WHO PABS negotiations (IGWG 5)
Co-chairs, Thank you for the opportunity to say a few words.Â
My comments address issues related to technology transfer (TT), a topic we have been...
Dolutegravir Patent Licences Can Provide Access To All
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential...
World Trade Organization Members Embark on Review of the TRIPS Agreement
The World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council will meet on 10-11 July. On the agenda is the review...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...